Литература

Kidney cancer. Principles and practice. Second edition. Primo N. Lara, Jr. Eric Jonasch (Editors). Springer International Publishing (2015)


  1. Frank I, Blute ML, Leibovich BC, Cheville JC, Lohse CM, Zincke H (2005) Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort. J Urol 173(6):1889–1892
  2. Leibovich BC, Blute ML, Cheville JC et al (2003) Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer 97(7):1663–1671
  3. Sargent DJ, Wieand HS, Haller DG et al (2005) Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 23(34):8664–8670
  4. Flocks RH, Kadesky MC (1958) Malignant neoplasms of the kidney; an analysis of 353 patients followed five years or more. J Urol 79(2):196–201
  5. Petkovic SD (1959) An anatomical classification of renal tumors in the adult as a basis for prognosis. J Urol 81(5):618–623
  6. Robson CJ (1963) Radical nephrectomy for renal cell carcinoma. J Urol 89:37–42
  7. Robson CJ, Churchill BM, Anderson W (1969) The results of radical nephrectomy for renal cell carcinoma. J Urol 101(3):297–301
  8. Hermanek P, Sobin LH (eds) (1987) TNM classification of malignant tumors, 4th edn. Springer, Berlin
  9. Sobin LH, Wittekind CL (eds) (1997) TNM classification of malignant tumours, 5th edn. Wiley-Liss, New York
  10. Greene FL, Page DL, Fleming ID et al (eds) (2002) AJCC cancer staging manual, 6th edn. Springer, New York
  11. Kidney (2010) In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds) AJCC cancer staging manual, 7th edn. Springer, New York, pp 479–490
  12. Klatte T, Patard JJ, Goel RH et al (2007) Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol 178(1): 35–40; discussion 40
  13. Delahunt B, Kittelson JM, McCredie MR, Reeve AE, Stewart JH, Bilous AM (2002) Prognostic importance of tumor size for localized conventional (clear cell) renal cell carcinoma: assessment of TNM T1 and T2 tumor categories and comparison with other prognostic parameters. Cancer 94(3):658–664
  14. Tsui KH, Shvarts O, Smith RB, Figlin RA, deKernion JB, Belldegrun A (2000) Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 163(4):1090–1095; quiz 1295
  15. Amin MB, Tamboli P, Javidan J et al (2002) Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol 26(3):281–291
  16. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168(6): 2395–2400
  17. Zisman A, Pantuck AJ, Dorey F et al (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19(6): 1649–1657
  18. Zisman A, Pantuck AJ, Wieder J et al (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 20(23): 4559–4566
  19. Patard JJ, Kim HL, Lam JS et al (2004) Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22(16):3316–3322
  20. Zigeuner R, Hutterer G, Chromecki T et al (2010) External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol 57(1):102–109
  21. Cindolo L, Chiodini P, Gallo C et al (2008) Validation by calibration of the UCLA integrated staging system prognostic model for nonmetastatic renal cell carcinoma after nephrectomy. Cancer 113(1):65–71
  22. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166(1):63–67
  23. Sorbellini M, Kattan MW, Snyder ME et al (2005) A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 173(1):48–51
  24. Concolino G, Marocchi A, Conti C, Tenaglia R, Di Silverio F, Bracci U (1978) Human renal cell carcinoma as a hormone-dependent tumor. Cancer Res 38(11 Pt 2):4340–4344
  25. Bono AV, Benvenuti C, Gianneo E, Comeri GC, Roggia A (1979) Progestogens in renal cell carcinoma. A retrospective study. Eur Urol 5(2):94–96
  26. Satomi Y, Takai S, Kondo I, Fukushima S, Furuhata A (1982) Postoperative prophylactic use of progesterone in renal cell carcinoma. J Urol 128(5):919–922
  27. Pizzocaro G, Piva L, Di Fronzo G et al (1987) Adjuvant medroxyprogesterone acetate to radical nephrectomy in renal cancer: 5-year results of a prospective randomized study. J Urol 138(6):1379–1381
  28. Yagoda A, Abi-Rached B, Petrylak D (1995) Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 22(1):42–60
  29. Masuda F, Nakada J, Kondo I, Furuta N (1992) Adjuvant chemotherapy with vinblastine, adriamycin, and UFT for renal-cell carcinoma. Cancer Chemother Pharmacol 30(6):477–479
  30. Naito S, Kumazawa J, Omoto T et al (1997) Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group. Int J Urol 4(1):8–12
  31. Medical Research Council Renal Cancer Collaborators (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial Lancet. 353(9146):14–17
  32. Pyrhonen S, Salminen E, Ruutu M et al (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17(9):2859–2867
  33. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13(3):688–696
  34. Pizzocaro G, Piva L, Colavita M et al (2001) Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 19(2):425–431
  35. Messing EM, Manola J, Wilding G et al (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial. J Clin Oncol 21(7):1214–1222
  36. Negrier S, Escudier B, Lasset C et al (1998) Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 338(18):1272–1278
  37. Negrier S, Perol D, Ravaud A et al (2007) Medroxyprogesterone, interferon alfa-2a, interleukin
  38. 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110(11):2468–2477
  39. Gore ME, Griffin CL, Hancock B et al (2010) Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an openlabel randomised trial. Lancet 375(9715):641–648
  40. McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23(1):133–141
  41. Passalacqua R, Buzio C, Buti S et al (2007) Adjuvant low-dose interleukin-2 (IL2) plus interferone-alpha (IFN) in operable renal cell cancer (RCC). A phase III, randomized, multicenter, independent trial of the Italian Oncology Group for Clinical Research (GOIRC). J Clin Oncol 25(June 18s Suppl):LBA5028
  42. Atzpodien J, Kirchner H, Illiger HJ et al (2001) IL-2 in combination with IFNalpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: longterm results of a controlled randomized clinical trial. Br J Cancer 85(8):1130–1136
  43. Allen MJ, Vaughan M, Webb A et al (2000) Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer 83(8):980–985
  44. Atzpodien J, Schmitt E, Gertenbach U et al (2005) Adjuvant treatment with interleukin-2and interferonalpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy: results of a prospectively randomised trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). Br J Cancer 92(5):843–846
  45. Aitchison M, Bray CA, Van Poppel H et al (2014) Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carci-
  46. noma: results of a phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial. Eur J Cancer 50(1):70–77
  47. Clark JI, Atkins MB, Urba WJ et al (2003) Adjuvant high-dose bolus interleukin-2 for patients with highrisk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21(16):3133–3140
  48. McDermott DF, Ghebremichael MS, Signoretti S et al (2010) The high-dose aldesleukin (HD IL-2) “SELECT” trial in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 28(15s):(suppl; abstr 4514)
  49. Sawczuk IS, Graham SDJ, Miesowicz F, Group AAS (1997) Randomized, controlled trial of adjuvant therapy with ex vivo activated T cells (ALT) in T1-3a,b,c or T4N+,M0 renal cell carcinoma (Meeting abstract). J Clin Oncol:16(Abstract 1163)
  50. Treisman JS, Morris R, Garlie N, Lefever A, Hanson JP (2008) Adjuvant activated T-cell (ATC) therapy for patients with non-metastatic or resected metastatic renal cell carcinoma. J Clin Oncol 26(May 20 suppl): (Abstract 5041)
  51. Asemissen AM, Brossart P (2009) Vaccination strategies in patients with renal cell carcinoma. Cancer Immunol Immunother 58(7):1169–1174
  52. Adler A, Gillon G, Lurie H et al (1987) Active specific immunotherapy of renal cell carcinoma patients: a prospective randomized study of hormono-immunoversus hormonotherapy. Preliminary report of immunological and clinical aspects. J Biol Response Mod 6(6):610–624
  53. Galligioni E, Quaia M, Merlo A et al (1996) Adjuvant immunotherapy treatment of renal carcinoma patients with autologous tumor cells and bacillus CalmetteGuerin: five-year results of a prospective randomized study. Cancer 77(12):2560–2566
  54. Jocham D, Richter A, Hoffmann L et al (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363(9409):594–599
  55. Repmann R, Wagner S, Richter A (1997) Adjuvant therapy of renal cell carcinoma with active-specificimmunotherapy (ASI) using autologous tumor vaccine. Anticancer Res 17(4B):2879–2882
  56. Repmann R, Goldschmidt AJ, Richter A (2003) Adjuvant therapy of renal cell carcinoma patients with an autologous tumor cell lysate vaccine: a 5-year follow-up analysis. Anticancer Res 23(2A): 969–974
  57. Doehn C, Richter A, Theodor RA, Lehmacher W, Jocham D (2007) An adjuvant vaccination with Reniale prolongs survival in patients with renal cell carcinoma following radical nephrectomy: secondary analysis of a multicenter phase-III trial [abstract #500]. J Urol 177(Suppl):167
  58. May M, Brookman-May S, Hoschke B et al (2010) Tenyear survival analysis for renal carcinoma patients treated with an autologous tumour lysate vaccine in an adjuvant setting. Cancer Immunol Immunother 59(5):687–695
  59. Wood C, Srivastava P, Bukowski R et al (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372(9633):145–154
  60. Wood CG, Srivastava P, Lacombe L et al (2009) Survival update from a multicenter, randomized, phase III trial of vitespen versus observation as adjuvant therapy for renal cell carcinoma in patients at high risk of recurrence. J Clin Invest 27(supplement):3009
  61. Stillebroer AB, Mulders PF, Boerman OC, Oyen WJ, Oosterwijk E (2010) Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur Urol 58(1):75–83
  62. Surfus JE, Hank JA, Oosterwijk E et al (1996) Antirenal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 19(3): 184–191
  63. Bleumer I, Knuth A, Oosterwijk E et al (2004) A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 90(5):985–990
  64. Davis ID, Wiseman GA, Lee FT et al (2007) A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer Immun 7:13
  65. Belldegrun A, Chamie K, Kloepfer P et al (2013) ARISER: a randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC—results and implications for adjuvant clinical trials. J Clin Oncol 31:(suppl; abstr 4507)
  66. Motzer RJ, Berg W, Ginsberg M et al (2002) Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 20(1):302–306
  67. Eisen T, Boshoff C, Mak I et al (2000) Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 82(4):812–817
  68. Margulis V, Matin SF, Tannir N et al (2009) Randomized trial of adjuvant thalidomide versus observation in patients with completely resected highrisk renal cell carcinoma. Urology 73(2):337–341
  69. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356(2):125–134
  70. Escudier B, Eisen T, Stadler WM et al (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27(20):3312–3318
  71. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Lancet 370(9605):2103–2111
  72. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renalcell carcinoma. N Engl J Med 356(22):2271–2281
  73. Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449–456
  74. Motzer RJ, Hutson TE, Tomczak P et al (2009) Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27(22):3584–3590
  75. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 356(2):115–124
  76. Rini BI, Halabi S, Rosenberg JE et al (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26(33):5422–5428
  77. Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061–1068
  78. Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. Cancer 116(18):4256–4265
  79. Rini BI, Escudier B, Tomczak P et al (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931–1939
  80. Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery. http://clinicaltrials.gov/ct2/show/NCT00326898
  81. A clinical trial comparing efficacy and safety of sunitinib versus placebo for the treatment of patients at high risk of recurrent renal cell cancer (S-TRAC). http://clinicaltrials.gov/show/NCT00375674
  82. Sorafenib in treating patients at risk of relapse after undergoing surgery to remove kidney cancer. http:// clinicaltrials.gov/ct/show/NCT00492258
  83. A study to evaluate pazopanib as an adjuvant treatment for localized renal cell carcinoma (RCC) (PROTECT). http://clinicaltrials.gov/show/NCT01235962
  84. Everolimus in treating patients with kidney cancer who have undergone surgery. http://clinicaltrials.gov/ ct/show/NCT01120249
  85. Adjuvant axitinib therapy of renal cell cancer in high risk patients (ATLAS). http://clinicaltrials.gov/show/ NCT01599754
  86. Haas NB, Manola J, Uzzo RG et al (2015) Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOGACRIN-led, NCTN phase III trial. J Clin Oncol 33:(suppl 7; abstr 403)
  87. Janowitz T, Welsh SJ, Zaki K, Mulders P, Eisen T (2013) Adjuvant therapy in renal cell carcinoma-past, present, and future. Semin Oncol 40(4):482–491
  88. Norton L, Simon R (1977) Tumor size, sensitivity to therapy, and design of treatment schedules. Cancer Treat Rep 61(7):1307–1317
  89. Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816
  90. Joensuu H, Eriksson M, Sundby Hall K et al (2012) One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 307(12):1265–1272

[contact-form-7 id=»5168″ title=»Контактная форма 1″]

0

Добавить комментарий

Войти с помощью: 

Ваш e-mail не будет опубликован. Обязательные поля помечены *